| Literature DB >> 32547841 |
Monica Javidnia1,2,3,4,5, Mark Frasier1,2,3,4,5, Ira Shoulson1,2,3,4,5, Ibrahim Turkoz1,2,3,4,5, Kumar Budur1,2,3,4,5.
Abstract
The International Society for Central Nervous System Clinical Trials and Methodology (ISCTM) partnered with the Michael J. Fox Foundation for Parkinson's Research to hold a joint session on innovation in Parkinson's disease research at the ISCTM 14th Annual Scientific Meeting held February 20 to 22, 2018 in Washington, D.C. The session focused on (1) biomarkers and outcomes measures in Parkinson's disease clinical trials; 2) clinical trial designs, outcomes, and statistical approaches; and 3) the path forward. This paper aims to summarize key takeaways from the session presenters, panelists, and audience members.Entities:
Keywords: Parkinson’s disease; RBD; disease modification; disease progression; prodromal
Year: 2020 PMID: 32547841 PMCID: PMC7239563
Source DB: PubMed Journal: Innov Clin Neurosci ISSN: 2158-8333